PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-25.63%
Both companies show negative ROE. Martin Whitman would check if the entire market segment is distressed.
-11.45%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
-14.18%
Both companies show negative ROCE. Martin Whitman would investigate if external factors hamper profitability.
-145.68%
Negative margin while TRAW has 92.86%. Joel Greenblatt would demand urgent cost or pricing measures.
-12769.14%
Both companies are negative at the operating level. Martin Whitman would see if the entire niche faces fundamental challenges.
-11511.11%
Both companies run at a net loss. Martin Whitman would see if broader market headwinds persist.